Study guide
12.2 Preeclampsia, Eclampsia & Gestational Hypertension
Combined Medical Services Examination UPSC CMS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Logistics & Pattern
1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths
2 Chapter 2: General Medicine - Cardiology & Respiratory
2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism
3 Chapter 3: General Medicine - Gastroenterology & Hepatology
3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes
4 Chapter 4: General Medicine - Nephrology & Endocrinology
4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction
5 Chapter 5: General Medicine - Neurology, Haematology & Infection
5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue
6 Chapter 6: General Medicine - Emergency Medicine & Toxicology
6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology
7 Chapter 7: Paediatrics - Neonatology & Child Growth
7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones
8 Chapter 8: Paediatrics - Child Health & Nutrition
8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning
9 Chapter 9: Surgery - General Surgery, Wounds & Shock
9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery
10 Chapter 10: Surgery - Surgical Specialties I
10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi
11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia
11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease
12 Chapter 12: Obstetrics - Antenatal Care & Complications
12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management
13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH
13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care
14 Chapter 14: Gynaecology & Family Planning
14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods
15 Chapter 15: PSM - Epidemiology & Biostatistics
15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing
16 Chapter 16: PSM - Disease Epidemiology & Programmes
16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling
17 Chapter 17: PSM - Health Planning & Environmental Health
17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education
12.2 Preeclampsia, Eclampsia & Gestational Hypertension
Key Takeaways Explain This Topic AI
Preeclampsia is diagnosed by new-onset hypertension (BP ≥140/90 mmHg after 20 weeks) accompanied by proteinuria (≥300 mg/24h) or features of severe end-organ dysfunction.
Defective trophoblastic invasion of uterine spiral arteries leads to placental ischemia, systemic endothelial dysfunction, and anti-angiogenic factor release (sFlt-1).
Magnesium sulfate (MgSO4) is the drug of choice for eclamptic seizures, requiring monitoring of patellar reflexes, respiratory rate (>16/min), and urine output (>30 mL/hr).
Calcium gluconate (10 mL of 10% solution IV) is the specific antidote for magnesium sulfate toxicity.
ACE inhibitors and ARBs are strictly contraindicated in pregnancy due to risks of fetal renal dysgenesis, oligohydramnios, and skull hypoplasia.
Last updated: July 2026
12.2 Preeclampsia, Eclampsia & Gestational Hypertension
Hypertensive disorders of pregnancy complicate 5–10% of all pregnancies worldwide and represent one of the lethal triad of maternal mortality (alongside hemorrhage and infection). Understanding the diagnostic boundaries, systemic pathophysiology, and emergency pharmacotherapy is essential for clinical practice and competitive examinations.
1. Classification & Diagnostic Criteria
According to the National High Blood Pressure Education Program (NHBPEP) and American College of Obstetricians and Gynecologists (ACOG) guidelines, hypertensive disorders in pregnancy are classified into 5 distinct categories:
1. Gestational Hypertension
New-onset blood pressure elevation (Systolic BP ≥ 140 mmHg \ge 140\text{ mmHg} ≥ 140 mmHg and/or Diastolic BP ≥ 90 mmHg \ge 90\text{ mmHg} ≥ 90 mmHg ) measured on two occasions at least 4 hours apart after 20 weeks of gestation in a previously normotensive woman.
Absence of proteinuria or signs of end-organ dysfunction.
Blood pressure returns to normal by 12 weeks postpartum.
2. Preeclampsia
New-onset hypertension (SBP ≥ 140 \ge 140 ≥ 140 or DBP ≥ 90 mmHg \ge 90\text{ mmHg} ≥ 90 mmHg after 20 weeks) PLUS :
Proteinuria: ≥ 300 mg \ge 300\text{ mg} ≥ 300 mg in a 24-hour urine collection, or Protein-to-Creatinine Ratio (PCR) ≥ 0.3 mg/mg \ge 0.3\text{ mg/mg} ≥ 0.3 mg/mg , or urine dipstick ≥ 1 + \ge 1+ ≥ 1 + (if quantitative methods unavailable).
Preeclampsia without Proteinuria: In the absence of proteinuria, preeclampsia is diagnosed if new-onset hypertension is accompanied by any of the following severe end-organ features:
Thrombocytopenia: Platelet count < 100 , 000 / μ L < 100,000/\mu\text{L} < 100 , 000/ μ L .
Renal Insufficiency: Serum creatinine > 1.1 mg/dL > 1.1\text{ mg/dL} > 1.1 mg/dL or doubling of serum creatinine in the absence of other renal disease.
Impaired Liver Function: Elevated blood transaminases (AST/ALT) to twice the upper limit of normal, or severe persistent right upper quadrant/epigastric pain.
Pulmonary Edema.
Cerebral / Visual Symptoms: New-onset persistent headache, scotomata, photopsia, or altered mental status.
3. Severe Features of Preeclampsia
Presence of any one of the following criteria upgrades the diagnosis to Preeclampsia with Severe Features :
SBP ≥ 160 mmHg \ge 160\text{ mmHg} ≥ 160 mmHg or DBP ≥ 110 mmHg \ge 110\text{ mmHg} ≥ 110 mmHg on two occasions at least 15 minutes apart.
Platelets < 100 , 000 / μ L < 100,000/\mu\text{L} < 100 , 000/ μ L .
Serum creatinine > 1.1 mg/dL > 1.1\text{ mg/dL} > 1.1 mg/dL .
AST or ALT > 2 × > 2\times > 2 × upper limit of normal, or severe epigastric/RUQ pain.
Pulmonary edema.
New-onset visual or neurological disturbances.
4. Eclampsia
Development of new-onset generalized tonic-clonic seizures in a woman with preeclampsia that cannot be attributed to other neurological causes (e.g., epilepsy, intracranial hemorrhage, meningitis).
5. Chronic Hypertension & Superimposed Preeclampsia
Chronic Hypertension: Hypertension present before pregnancy or diagnosed before 20 weeks of gestation, or persisting beyond 12 weeks postpartum.
Superimposed Preeclampsia: Chronic hypertension with new-onset proteinuria or sudden escalation of BP or development of systemic severe features after 20 weeks.
- 2. Pathophysiology & HELLP Syndrome
- Two-Stage Model of Pathophysiology
Stage 1 (Placental Stage): Abnormal endovascular trophoblastic invasion of the maternal spiral arteries between 16 and 20 weeks of gestation. The spiral arteries fail to transform from narrow, high-resistance muscular vessels into wide, low-resistance non-muscular vascular channels. This results in placental hypoperfusion, ischemia, and hypoxia.
Stage 2 (Maternal Systemic Stage): The ischemic placenta releases anti-angiogenic factors into maternal circulation, primarily soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng) . These factors bind and neutralize vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), precipitating widespread maternal endothelial cell dysfunction , generalized vasospasm, capillary leakage, intravascular volume depletion, and microvascular thrombosis. [Defective Trophoblastic Invasion] -> [Placental Hypoxia/Ischemia]
- |
- v
- [Anti-Angiogenic Release: sFlt-1, sEng] -> [Systemic Endothelial Dysfunction]
- |
- +-------------------+-----------------+-------------------+
- | | | |
- v v v v
- [Vasospasm & HTN] [Capillary Leak] [Microthrombosis] [Organ Hypoperfusion]
- | | | |
- (SBP >= 140) (Proteinuria/ (Thrombocytopenia, (Headache, HELLP,
- Edema) Microangiopathy) Renal Impairment)
- HELLP Syndrome
A severe variant of preeclampsia characterized by:
H (Hemolysis): Microangiopathic hemolytic anemia with fragmented RBCs (schistocytes) on peripheral blood smear, total bilirubin ≥ 1.2 mg/dL \ge 1.2\text{ mg/dL} ≥ 1.2 mg/dL , elevated serum Lactate Dehydrogenase (LDH > 600 U/L > 600\text{ U/L} > 600 U/L ).
EL (Elevated Liver Enzymes): AST and ALT > 70 U/L > 70\text{ U/L} > 70 U/L (twice normal).
LP (Low Platelets): Platelet count < 100 , 000 / μ L < 100,000/\mu\text{L} < 100 , 000/ μ L .
3. Management of Eclampsia & Magnesium Sulfate Protocols
Magnesium Sulfate ( M g S O 4 MgSO_4 M g S O 4 ) is the anticonvulsant drug of choice for the prevention of eclampsia in preeclampsia with severe features and for treating eclamptic seizures (superior to diazepam, phenytoin, or lytic cocktail in the MAGPIE trial).
Administration Protocols
Protocol Parameter Pritchard Regimen (IM / IV Combined) Zuspan Regimen (Intravenous Continuous)
Loading Dose 4 g IV (20% solution over 5–10 min) PLUS 10 g IM (5 g of 50% solution deep IM into each buttock) 4–6 g IV (20% solution over 15–20 min)
Maintenance Dose 5 g IM of 50% solution in alternate buttocks every 4 hours 1–2 g/hour continuous IV infusion
Duration Continued for 24 hours after delivery or 24 hours after the last seizure (whichever is later) Continued for 24 hours post-delivery or post-last seizure
Mandatory Clinical Monitoring Parameters BEFORE Each Maintenance Dose
M g S O 4 MgSO_4 M g S O 4 is excreted exclusively by the kidneys. To avoid life-threatening toxicity, the following three mandatory clinical criteria must be evaluated prior to administering each maintenance dose:
Patellar Reflex (Knee Jerk): Must be PRESENT . (Loss of deep tendon reflexes is the earliest clinical sign of toxicity, occurring at serum levels of 8–12 mEq/L).
Respiratory Rate: Must be > 16 breaths/minute > 16\text{ breaths/minute} > 16 breaths/minute . (Respiratory depression occurs at serum levels of 12–16 mEq/L).
Urine Output: Must be > 30 mL/hour > 30\text{ mL/hour} > 30 mL/hour (or > 100 mL > 100\text{ mL} > 100 mL over the preceding 4 hours).
MgSO4 Serum Toxicity Levels & Antidote
Therapeutic Serum Level: 4.0–7.0 mEq/L (4.8–8.4 mg/dL).
Loss of Patellar Reflex: 8.0–10.0 mEq/L.
Respiratory Depression: 12.0 mEq/L.
Cardiac Arrest / Asystole: > 15.0 mEq/L > 15.0\text{ mEq/L} > 15.0 mEq/L .
Specific Antidote: Calcium Gluconate 10 mL of 10% solution IV administered slowly over 10 minutes.